Skip to main content
    E

    Equillium Inc (EQ)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.32
    +0.02 (+1.54%)

    Market Cap: $83.70M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    56%(18/32)
    Avg Surprise
    +6.30%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.05
    Range$-0.06 - $-0.04
    7 analysts
    EPS Revisions
    2
    0
    7d
    2
    3
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.05-2.8%
    60d ago$-0.05-0.2%
    30d ago$-0.050.0%
    7d ago$-0.050.0%
    Current$-0.05
    Revenue Consensus
    $0
    Range$0 - $0
    9 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.05
    Range$-0.06 - $-0.01
    7 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    9 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.05---
    Sep 26EST
    		-$-0.05---
    Jun 26
    Reported Aug 13
    		$-0.04$-0.05+20.00%Beat+75.0%
    Mar 26
    Reported May 13
    		$-0.06$-0.04-50.00%Miss+75.0%
    Dec 25
    Reported Mar 25
    		$-0.04$-0.07+42.86%Beat+75.0%
    Sep 25
    Reported Nov 13
    		$-0.06N/A+72.73%Beat-29900.0%
    Jun 25
    Reported Aug 14
    		$-0.16$-0.18+11.11%Beat-1700.0%
    Mar 25
    Reported May 14
    		$-0.24$-0.33+27.27%Beat-200.0%
    Dec 24
    Reported Mar 27
    		$-0.16$-0.31+48.39%Beat-128.6%
    Sep 24
    Reported Nov 13
    		$-0.00N/A-100.14%Miss+99.8%
    Jun 24
    Reported Aug 8
    		$0.01N/A+107.69%Beat+110.0%
    Mar 24
    Reported May 9
    		$-0.08$-0.11+27.27%Beat+27.3%
    Dec 23
    Reported Mar 25
    		$-0.07N/A+58.82%Beat-187.5%
    Sep 23
    Reported Nov 8
    		$-0.11$-0.12+8.33%Beat+72.5%
    Jun 23
    Reported Aug 9
    		$-0.10$-0.11+9.09%Beat+75.6%
    Mar 23
    Reported May 11
    		$-0.11$-0.06-83.33%Miss+90.6%
    Dec 22
    Reported Mar 23
    		$0.08$-0.03+366.67%Beat+122.2%
    Sep 22
    Reported Nov 14
    		$-0.40$-0.37-8.11%Miss-14.3%
    Jun 22
    Reported Aug 15
    		$-0.41$-0.40-2.50%Miss-32.3%
    Mar 22
    Reported May 12
    		$-1.17$-0.38-207.89%Miss-254.5%
    Dec 21
    Reported Mar 23
    		$-0.36$-0.34-5.88%Miss+0.0%
    Sep 21
    Reported Nov 10
    		$-0.35$-0.34-2.94%Miss-12.9%
    Jun 21
    Reported Aug 10
    		$-0.31$-0.32+3.13%Beat+16.2%
    Mar 21
    Reported May 13
    		$-0.33$-0.32-3.13%Miss+26.7%
    Dec 20
    Reported Mar 24
    		$-0.36$-0.40+10.00%Beat+18.2%
    Sep 20
    Reported Nov 10
    		$-0.31$-0.44+29.55%Beat+11.4%
    Jun 20
    Reported Aug 12
    		$-0.37$-0.44+15.91%Beat-5.7%
    Mar 20
    Reported May 13
    		$-0.45$-0.41-9.76%Miss-32.4%
    Dec 19
    Reported Mar 26
    		$-0.44$-0.39-12.82%Miss-41.9%
    Sep 19
    Reported Nov 12
    		$-0.35$-0.42+16.67%Beat-12.9%
    Jun 19
    Reported Aug 12
    		$-0.35$-0.41+14.63%Beat-150.0%
    Mar 19
    Reported May 13
    		$-0.34$-0.30-13.33%Miss-
    Dec 18
    Reported Mar 27
    		$-0.31$-0.29-6.90%Miss-
    Sep 18
    Reported Oct 12
    		$-0.31$-0.11-181.82%Miss-
    Jun 18
    Reported Aug 3
    		$-0.14$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-6.60EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-59.00%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio23.40xQuick Ratio23.40x
    Trading Statistics
    Beta1.92Avg Volume726.17K
    52-Week High$3.5452-Week Low$0.76

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.40
    SMA 20$1.57
    SMA 50$1.97
    SMA 200$2.08
    EMA 10$1.42
    EMA 20$1.57
    EMA 50$1.88
    EMA 200$1.97

    MACD

    Line: -0.20Signal: -0.20Hist: -0.00

    ADX

    ADX: 32.2+DI: 11.1-DI: 27.8

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down100.0
    PSAR$1.51

    Bollinger Bands

    Upper Band$1.97
    Lower Band$1.16
    %B Position5180%(Upper)
    Band Width0.20

    RSI (14-Day)

    Neutral
    30.7

    Momentum Oscillators

    Stoch %K4.5
    Stoch %D11.7
    Williams %R-90.9
    ROC (10d)-14.3%
    Momentum-0.22
    CCI (20d)-95.9
    MFI (14d)19.7

    Volatility Measures

    ATR (14d)$0.13(10.2%)
    StdDev (20d)0.20
    Hist Vol71.5%(High)

    Volume Flow

    VWAP$1.32
    OBV477.1M
    AD Line-243.6M
    CMF (20d)0.127

    Volume Metrics

    Avg Vol (20d)724.9K
    Vol Ratio0.7x
    VWMA (20d)$1.64

    Pivot Points

    R3$1.43
    R2$1.41
    R1$1.35
    Pivot Point$1.33
    S1$1.27
    S2$1.25
    S3$1.19

    Advanced Oscillators

    TSI-38.83
    Ultimate Osc41.9
    KST-322.81

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$4.39M$12.16M$13.85M$10.69M$9.21M$8.87M
    Cost of RevenueN/A$24,000$23,000$28,000$32,000$33,000$35,000$35,000$35,000$32,000$33,000$31,000
    Gross ProfitN/A$-24,000$-23,000$-28,000$-32,000$-33,000$4.39M$12.16M$13.85M$10.66M$9.18M$8.87M
    Operating Expenses$5.16M$5.59M$3.94M$4.58M$6.20M$8.87M$9.09M$12.84M$13.95M$13.45M$12.38M$12.49M
    R&D$2.75M$2.99M$1.54M$1.30M$4.08M$5.92M$7.32M$9.56M$10.81M$9.74M$9.18M$8.97M
    SG&A$2.41M$2.62M$2.43M$3.27M$2.15M$2.95M$1.77M$3.28M$3.15M$3.74M$3.23M$3.52M
    Operating Income$-5,155,000$-5,610,000$-3,962,000$-4,575,000$-6,228,000$-8,870,000$-4,698,000$-679,000$-100,000$-2,791,000$-3,200,000$-3,623,000
    Interest Income$509,000$309,000$303,000$235,000$122,000$173,000$239,000$331,000$371,000$439,000$517,000$551,000
    Interest Expense$0$0$0$0$0$0$0$0$0$0$982,000$0
    Income Before Tax$-4,693,000$-5,311,000$-3,775,000$-4,230,000$-5,739,000$-8,654,000$-5,433,000$-7,000$468,000$-2,734,000$-2,326,000$-3,214,000
    Income Tax Expense$0$0$0$0$0$0$361,000$0$0$-11,276$16,000$496,000
    Net Income$-4,693,000$-5,311,000$-3,775,000$-4,230,000$-5,739,000$-8,654,000$-5,794,000$-7,000$468,000$-2,734,000$-2,342,000$-3,710,000
    EBITDA$-5,082,000$-5,287,000$-3,752,000$-4,202,000$-5,707,000$-8,621,000$-5,398,000$28,000$503,000$-2,702,000$-2,293,000$-3,183,000
    EBIT$-5,108,000$-5,311,000$-3,775,000$-4,230,000$-5,739,000$-8,654,000$-5,433,000$-7,000$468,000$-2,734,000$-2,326,000$-3,214,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about EQ

    News

    This biotech stock has a massive upside, Roth says

    Roth Capital Partners analyst Adam Walsh reiterated a "Buy" rating and US$12.00 target for Equillium, citing increased potential value for its EQ302 program due to new celiac disease data. Although EQ302 currently has no...

    Cantech Letter•10/14/26•Bullish

    Analysts’ Top Healthcare Picks: Equillium (EQ), NeoGenomics (NEO)

    Two analysts have issued bullish sentiments on healthcare stocks Equillium (EQ) and NeoGenomics (NEO). Piper Sandler maintained a Buy rating on Equillium with a $20.00 price target...

    The Globe and Mail•10/8/26•Bullish

    Equillium Advances EQ504 With Phase 1 Trial Clearance

    Equillium, Inc. has received approval to begin a Phase 1 clinical trial for its oral candidate EQ504 in Australia, with the first participant dosing expected by early November 2026. The trial will assess safety...

    The Globe and Mail•10/7/26•Somewhat-Bullish

    Equillium Announces Poster Presentation at the 50th Anniversary La Jolla Immunology Conference

    Equillium, Inc. announced new preclinical data for its EQ504 program would be presented at the 50th Anniversary La Jolla Immunology Conference. The data highlights EQ504's multi-modal activity...

    GlobeNewswire•10/7/26•Bullish

    Equillium Advances EQ504 With Phase 1 Trial Clearance

    Equillium announced it has secured clearance for a Phase 1 clinical trial of its oral candidate EQ504 in Australia, with first dosing expected by early November 2026. The trial will assess safety, tolerability...

    The Globe and Mail•10/7/26•Neutral

    EQ Valuation and Fair Value

    P/E
    -6.6x
    Forward P/E
    1.5x
    P/B
    2.6x
    See GNG's fair value

    EQ Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -59.0%
    FCF margin
    -457.4%

    EQ Competitors

    CompanyTicker
    Forian IncFORA
    Neuraxis, Inc.NRXS
    Rallybio CorpRLYB
    Sera Prognostics IncSERA
    Hyperfine IncHYPR
    Cardiff Oncology IncCRDF
    Immunic IncIMUX
    Lixte Biotechnology Holdings IncLIXT

    Sector: Healthcare

    EQ Analyst Ratings

    Consensus
    Buy
    Analysts
    9
    Strong Buy
    1
    Buy
    8
    Hold
    0
    Sell
    0
    Strong Sell
    0

    EQ Bull Case vs Bear Case

    Bull case

    • EQ beat EPS estimates in 75.0% of its last 8 reported quarters.
    • 100.0% of EQ's analyst ratings are Buy or Strong Buy.

    Bear case

    • EQ's quarterly revenue changed -52.3% year over year.

    EQ Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    9.0%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.05
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    2 up, 3 down

    Frequently Asked Questions About EQ

    Does EQ pay dividends?

    Equillium Inc (EQ) does not currently pay a regular dividend.

    What is EQ's market cap?

    Equillium Inc (EQ) has a market capitalization of $83.70M with a current stock price of $1.32.

    Related stocks

    Sector: Healthcare

    All stocks starting with E

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In